Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 2

Sıçanlarda mitoksantronun yol açtığı akut kardiyotoksisteye karşı amifostin ile miyokardın korunması

The protection of the myocardium by amifostine against mitoxantrone-induced acute cardiotoxicity in rats

Pages
62–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

AMI can protect against MITO-induced acute cardiotoxicity, decreasing myocardial damage and lipid peroxidation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Amifostine (AMI) has been used for the prevention of doxorubiciinduced cardiotoxicity in several experimental and a few clinical studies.
📊
Key Findings & Data:Materials and Methods: Thirty-six rats were divided into six groups (n=6 in each).
💡
Conclusion & Impact:AMI can protect against MITO-induced acute cardiotoxicity, decreasing myocardial damage and lipid peroxidation.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Amifostine (AMI) has been used for the prevention of doxorubiciinduced cardiotoxicity in several experimental and a few clinical studies. The aim of this study was to investigate the effects of AMI on lipid peroxidation, protective enzymes, and mitoxantrone (MITO)-induced acute cardiotoxicity in the rat heart using biochemical tests and histopathological examinations. Materials and Methods: Thirty-six rats were divided into six groups (n=6 in each). Control rats were given intraperitoneal (i.p.) serum saline and AMI group rats were given 200 mg/kg AMI i.p. Rats received MITO-2.5 and 5 mg/kg i.p. in the MITO-2.5 and MITO-5 groups. AMI 200 mg/kg i.p. was administered 30 min. before the same doses of MITO in the MITO-2.5+AMI and MITO-5+AMI groups. Results: The levels of cardiac enzymes such as creatinine phosphokinasemyocardial band and cardiac troponin T did not change. Malondialdehyde (MDA) levels increased in MITO groups compared to controls. Catalase and glutathione (GSH) levels in the MITO and MITO+AMI groups were higher than in controls. Superoxide dismutase and glutathione peroxidase levels were not different between MITO groups and controls. There was no difference in MDA levels between MITO+AMI groups and controls. Calcium deposition was not detected. The scores of fibrosis, apoptosis, inflammation, and degeneration in MITO groups were higher than in controls. The scores of fibrosis, degeneration and inflammation in MITO+AMI groups were lower. Conclusion: MITO caused lipid peroxidation and myocardial damage, and the myocardium increased catalase and GSH levels to prevent this damage. AMI can protect against MITO-induced acute cardiotoxicity, decreasing myocardial damage and lipid peroxidation.

Özet

Amaç: Amifostin (AMI) doksorubisinin yol açtığı kardiyotoksisiteden korunmada çeşitli deneysel ve bir kaç klinik çalışmada kullanılmıştır. Bu çalışmanın amacı Sıçan kalbindeki lipid peroksidasyonu, koruyucu enzimler ve mitoksantronun (MITO) yol açtığı akut kardiyotoksisite üzerinde AMI’nin etkilerini biyokimyasal ve histopatolojik incelemeler ile araştırmaktı. Yöntem ve Gereçler: Her bir grupta 6 sıçan olmak üzere 36 sıçan 6 gruba bölündü. İntraperitoneal (ip) olarak kontrol grubuna serum fizyolojik ve AMI grubuna 200 mg/kg AMI verildi. MITO 2.5 ve 5 gruplarındaki sıçanlar ip MITO 2.5 ve 5 mg/kg aldı. MITO 2.5+AMI ve MITO 5+AMI gruplarında aynı dozlarda MITO’dan 30 dk önce 200 mg/kg AMI uygulandı. Bulgular: Kretainin fosfokinaz-miyokardial bant ve kardiyak troponin T gibi kardiyak enzimlerin düzeyi değişiklik göstermedi. MITO gruplarındaki malondialdehid (MDA) düzeyleri kontrollere kıyasla yüksekti. MITO ve MITO+AMI gruplarındaki katalaz ve glutatyon düzeyleri kontrollerden yüksekti. MITO+AMI ve kontroller arasında süperoksit dismutaz ve glutatyon peroksidaz düzeyleri bakımından fark yoktu. Kalsiyum birikimi saptanmadı. Fibrozis, dejenerasyon ve inflamasyon skorları MITO+AMI gruplarında daha düşüktü. Sonuç: MITO lipid peroksidasyonu ve miyokardiyal zaralanmaya neden olurken miyokardiyum bu zaralanmadan korunmak için katalaz ve GSH düzeylerini arttırmaktadır. AMI miyokardiyal zararlanma ve lipid peroksidasyonu azaltarak MITO’nun yol açtığı akut kardiyotoksisiteye karşı koruyucu olabilmektedir.

🔖

Cite This Article

KADIKÖYLÜ, V. G., METEOĞLU, İ., DEMİR, S., AYBEK, H., KALAK, M., BALKAYA, M., YENİSEY, Ç., BOLAMAN, Z. (2010). Sıçanlarda mitoksantronun yol açtığı akut kardiyotoksisteye karşı amifostin ile miyokardın korunması. Turkish Journal of Hematology, Cilt: 27 - Sayı: 2, 62–69. https://ajindex.com/articles/412924

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54:1-7
  2. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracycline: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229
  3. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58. 4. van Dalen EC, van der Pal HJH, Bakker PJ, Caron HN, Kremer LC. Cumulative incidence and risk factors of mitoxantroneinduced carditoxicity: a systematic review. Eur J Cancer 2004;40:643-52
  4. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-13
  5. Andersson BS, Eksborg S, Vidal RF, Sundberg M, Carlberg M. Anthraquinone–induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology 1999;135:11-20
  6. Kim E, Giri SN, Pessah IN. Antithetical actions of mitoxantrone and doxorubicin on ryanodine-sensitive Ca++ release channels of rat cardiac sarcoplasmic reticulum: evidence for a competitive mechanism. J Pharmacol Exp Ther 1994;268:1212-21
  7. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 1983:43:460-72
  8. Bolaman Z, Cicek C, Kadikoylu G, Barutca S, Serter M, Yenisey C, Alper G. The protective effects of amifostine on adriamycininduced acute cardiotoxicity in rats. Tohoku J Exp Med 2005:207:249-53
  9. Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E. Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 1986;46:54-60
  10. Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23: 23-34
  11. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tunes for and old song. FASEB J 1999;13:199-212
  12. Nazeyrollas P, Frances C, Prevost A, Costa B, Lorenzato M, Kantelip JP, Elaerts J, Millart H. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Anticancer Res 2003;23:405-9
  13. Dragojevic-Simic VM, Dobric SL, Bokonjic DR, Vucinic ZM, Jacevic VM, Dogovic NP. Amifostine protection against doxorubucin cardiotoxicity in rats. Anti-Cancer Drugs 2004;15:169-78
  14. Rigatos S, Stathopoulos G, Dontas I, Perrea-Kotsarelis D, Cou